The future of regulatory compliance and GMP in pharma, biotech, and medical device industries is being transformed by AI. AI-powered regulatory intelligence, predictive analytics, and automation are significantly improving compliance efficiency, but regulatory agencies are still defining the scope of AI governance in GMP.
By the end of this session, attendees will:
Areas Covered in the Session:-
Background:-
Artificial Intelligence (AI) is revolutionizing regulatory compliance, quality assurance, and GMP practices across the pharmaceutical, biotech, and medical device industries. As regulatory agencies such as the FDA, EMA, MHRA, and PMDA evolve their frameworks, AI is playing an increasingly vital role in automating compliance, ensuring data integrity, enhancing quality systems, and optimizing manufacturing processes.
This webinar, led by Dr. David Lim, Ph.D., will provide an in-depth exploration of how AI is reshaping regulatory affairs, GMP compliance, and quality management systems (QMS), helping companies navigate challenges in AI validation, regulatory expectations, and implementation strategies.
Why Should You Attend?
Regulatory agencies are tightening compliance requirements while companies struggle with manual, paper-based, and outdated quality management systems. AI is a game-changer, offering the potential to:
However, the regulatory landscape for AI in GMP compliance is still evolving, and improper AI implementation can lead to compliance risks, FDA warnings, and regulatory rejections.
This webinar will help you understand how to leverage AI responsibly and compliantly while avoiding pitfalls that could result in compliance failures and financial losses.
Who Will Benefit?